Sensitivity and specificity of clinical criteria for hereditary non-polyposis colorectal cancer associated mutations inMSH2 and MLH1

BACKGROUND AND AIMS There are multiple criteria for the clinical diagnosis of hereditary non-polyposis colorectal cancer (HNPCC). The value of several of the newer proposed diagnostic criteria in identifying subjects with mutations in HNPCC associated mismatch repair genes has not been evaluated, and the performance of the different criteria have not been formally compared with one another. METHODS We classified 70 families with suspected hereditary colorectal cancer (excluding familial adenomatous polyposis) by several existing clinical criteria for HNPCC, including the Amsterdam criteria, the Modified Amsterdam criteria, the Amsterdam II criteria, and the Bethesda criteria. The results of analysis of the mismatch repair genes MSH2and MLH1 by full gene sequencing were available for a proband with colorectal neoplasia in each family. The sensitivity and specificity of each of the clinical criteria for the presence of MSH2 andMLH1 mutations were calculated. RESULTS Of the 70 families, 28 families fulfilled the Amsterdam criteria, 39 fulfilled the Modified Amsterdam Criteria, 34 fulfilled the Amsterdam II criteria, and 56 fulfilled at least one of the seven Bethesda Guidelines for the identification of HNPCC patients. The sensitivity and specificity of the Amsterdam criteria were 61% (95% CI 43-79) and 67% (95% CI 50-85). The sensitivity of the Modified Amsterdam and Amsterdam II criteria were 72% (95% CI 58-86) and 78% (95% CI 64-92), respectively. Overall, the most sensitive criteria for identifying families with pathogenic mutations were the Bethesda criteria, with a sensitivity of 94% (95% CI 88-100); the specificity of these criteria was 25% (95% CI 14-36). Use of the first three criteria of the Bethesda guidelines only was associated with a sensitivity of 94% and a specificity of 49% (95% CI 34-64). CONCLUSIONS The Amsterdam criteria for HNPCC are neither sufficiently sensitive nor specific for use as a sole criterion for determining which families should undergo testing for MSH2 and MLH1mutations. The Modified Amsterdam and the Amsterdam II criteria increase sensitivity, but still miss many families with mutations. The most sensitive clinical criteria for identifying subjects with pathogenic MSH2 andMLH1 mutations were the Bethesda Guidelines; a streamlined version of the Bethesda Guidelines may be more specific and easier to use in clinical practice.

[1]  T. O'Leary.  Molecular diagnosis of hereditary nonpolyposis colorectal cancer. , 1999, JAMA.

[2]  J. Garber,et al.  Interpretation of genetic test results for hereditary nonpolyposis colorectal cancer: implications for clinical predisposition testing. , 1999, JAMA.

[3]  H T Lynch,et al.  New clinical criteria for hereditary nonpolyposis colorectal cancer (HNPCC, Lynch syndrome) proposed by the International Collaborative group on HNPCC. , 1999, Gastroenterology.

[4]  A. Zwinderman,et al.  Clinical findings with implications for genetic testing in families with clustering of colorectal cancer. , 1998, The New England journal of medicine.

[5]  L. Aaltonen,et al.  Incidence of hereditary nonpolyposis colorectal cancer and the feasibility of molecular screening for the disease. , 1998, The New England journal of medicine.

[6]  C. Boland,et al.  A National Cancer Institute Workshop on Hereditary Nonpolyposis Colorectal Cancer Syndrome: meeting highlights and Bethesda guidelines. , 1997, Journal of the National Cancer Institute.

[7]  R. Kucherlapati,et al.  Mutation in the Mismatch Repair Gene Msh6 Causes Cancer Susceptibility , 1997, Cell.

[8]  M. Koike,et al.  Germline mutation of MSH6 as the cause of hereditary nonpolyposis colorectal cancer , 1997, Nature Genetics.

[9]  P. Peltomäki,et al.  Mutations predisposing to hereditary nonpolyposis colorectal cancer: database and results of a collaborative study. The International Collaborative Group on Hereditary Nonpolyposis Colorectal Cancer. , 1997, Gastroenterology.

[10]  A. Viel,et al.  Hereditary nonpolyposis colorectal cancer: review of clinical, molecular genetics, and counseling aspects. , 1996, American journal of medical genetics.

[11]  K. Kinzler,et al.  Microsatellite instability and mutations of the transforming growth factor beta type II receptor gene in colorectal cancer. , 1995, Cancer research.

[12]  C. Boland,et al.  Hereditary nonpolyposis colorectal cancer: the syndrome, the genes, and historical perspectives. , 1995, Journal of the National Cancer Institute.

[13]  K. Kinzler,et al.  Inactivation of the type II TGF-beta receptor in colon cancer cells with microsatellite instability. , 1995, Science.

[14]  V. Lazar,et al.  Accumulation of multiple mutations in tumour suppressor genes during colorectal tumorigenesis in HNPCC patients. , 1994, Human molecular genetics.

[15]  H T Lynch,et al.  Hereditary Nonpolyposis Colorectal Cancer Patients Replication Errors in Benign and Malignant Tumors from , 2006 .

[16]  R. Fleischmann,et al.  Mutation of a mutL homolog in hereditary colon cancer. , 1994, Science.

[17]  D. Ward,et al.  Mutation in the DNA mismatch repair gene homologue hMLH 1 is associated with hereditary non-polyposis colon cancer , 1994, Nature.

[18]  Robin J. Leach,et al.  Mutations of a mutS homolog in hereditary nonpolyposis colorectal cancer , 1993, Cell.

[19]  N. Copeland,et al.  The human mutator gene homolog MSH2 and its association with hereditary nonpolyposis colon cancer , 1993, Cell.

[20]  L. Roncucci,et al.  Tumour spectrum in hereditary non‐polyposis colorectal cancer (HNPCC) and in families with “suspected hnpcc”. A population‐based study in northern Italy , 1993, International journal of cancer.

[21]  S N Thibodeau,et al.  Microsatellite instability in cancer of the proximal colon. , 1993, Science.

[22]  K. Kinzler,et al.  Clues to the pathogenesis of familial colorectal cancer. , 1993, Science.

[23]  J. Mecklin,et al.  The International Collaborative Group on Hereditary Non-Polyposis Colorectal Cancer (ICG-HNPCC) , 1991, Diseases of the colon and rectum.